{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "19376711",
  "DateCompleted": {
    "Year": "2009",
    "Month": "09",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "12",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2009",
        "Month": "03",
        "Day": "27"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.apradiso.2009.03.070"
    ],
    "Journal": {
      "ISSN": "1872-9800",
      "JournalIssue": {
        "Volume": "67",
        "Issue": "7-8 Suppl",
        "PubDate": {
          "Year": "2009",
          "Month": "Jul"
        }
      },
      "Title": "Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine",
      "ISOAbbreviation": "Appl Radiat Isot"
    },
    "ArticleTitle": "Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT.",
    "Pagination": {
      "StartPage": "S313",
      "EndPage": "S317",
      "MedlinePgn": "S313-7"
    },
    "Abstract": {
      "AbstractText": [
        "We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires, Argentina."
          }
        ],
        "LastName": "Monti Hughes",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Heber",
        "ForeName": "E M",
        "Initials": "EM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pozzi",
        "ForeName": "E",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Nigg",
        "ForeName": "D W",
        "Initials": "DW"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Calzetta",
        "ForeName": "O",
        "Initials": "O"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Blaumann",
        "ForeName": "H",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Longhino",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Nievas",
        "ForeName": "S I",
        "Initials": "SI"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Aromando",
        "ForeName": "R F",
        "Initials": "RF"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Itoiz",
        "ForeName": "M E",
        "Initials": "ME"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Trivillin",
        "ForeName": "V A",
        "Initials": "VA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Schwint",
        "ForeName": "A E",
        "Initials": "AE"
      }
    ],
    "PublicationTypeList": [
      "Evaluation Study",
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, Non-P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Appl Radiat Isot",
    "NlmUniqueID": "9306253",
    "ISSNLinking": "0969-8043"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Borohydrides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Boron Compounds"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Radiation-Sensitizing Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sulfhydryl Compounds"
    },
    {
      "RegistryNumber": "12294-22-3",
      "NameOfSubstance": "mercaptoundecahydrododecaborate"
    },
    {
      "RegistryNumber": "47E5O17Y3R",
      "NameOfSubstance": "Phenylalanine"
    },
    {
      "RegistryNumber": "57-97-6",
      "NameOfSubstance": "9,10-Dimethyl-1,2-benzanthracene"
    },
    {
      "RegistryNumber": "UID84303EL",
      "NameOfSubstance": "4-boronophenylalanine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "toxicity"
      ],
      "DescriptorName": "9,10-Dimethyl-1,2-benzanthracene"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacokinetics",
        "therapeutic use"
      ],
      "DescriptorName": "Borohydrides"
    },
    {
      "QualifierName": [
        "pharmacokinetics",
        "therapeutic use"
      ],
      "DescriptorName": "Boron Compounds"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Boron Neutron Capture Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cricetinae"
    },
    {
      "QualifierName": [
        "radiotherapy"
      ],
      "DescriptorName": "Mouth Neoplasms"
    },
    {
      "QualifierName": [
        "radiotherapy"
      ],
      "DescriptorName": "Neoplasm Recurrence, Local"
    },
    {
      "QualifierName": [
        "radiotherapy"
      ],
      "DescriptorName": "Neoplasms, Second Primary"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "pharmacokinetics",
        "therapeutic use"
      ],
      "DescriptorName": "Phenylalanine"
    },
    {
      "QualifierName": [
        "chemically induced",
        "metabolism",
        "pathology",
        "radiotherapy"
      ],
      "DescriptorName": "Precancerous Conditions"
    },
    {
      "QualifierName": [
        "pharmacokinetics",
        "therapeutic use"
      ],
      "DescriptorName": "Radiation-Sensitizing Agents"
    },
    {
      "QualifierName": [
        "pharmacokinetics",
        "therapeutic use"
      ],
      "DescriptorName": "Sulfhydryl Compounds"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Tissue Distribution"
    }
  ]
}